Impact of C-reactive protein on treatment of patients with cardiovascular disease

American Journal of Health-System Pharmacy

Volumn 64, Issue 19, 2007, Pages 2009-2016

  Gortney, Justine Schuller ^a   Sanders, Rhonda Martin ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Antilipemic agents; C reactive protein; Cardiovascular diseases; Drugs; Pravastatin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANAMNESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DRUG DOSE INCREASE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; PATIENT MONITORING; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 34948839476     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060542     Document Type: Review

References (34)

1. Braunwald E. Shattuck lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337:1360-9.
2. Grundy SM, Cleeman JI, Mertz CN et al. Implications of the recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39.
3. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557-65.
4. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107:363-9.
5. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
6. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973-9.
7. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after MI in patients with average cholesterol levels. Circulation. 1998; 98:839-44.
8. Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999; 100:230-5.
9. Ridker PM, Cannon CP, Rifai N et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352:20-8.
10. Cannon CP, Braunwald E, McCabe C et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-504.
11. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005; 96:53E-59E.
12. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499-511.
13. Torres J, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol. 2003; 18:471-8.
14. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352:1685-95.
15. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events. Circulation. 2003; 108:2317-22.
16. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med. 2004; 117:499-507.
17. Blake GJ, Rifai N, Buring J et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003; 108:2993-9.
18. Ridker PM. High sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103:1813-8.
19. Malik S, Wong ND, Franklin S et al. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care. 2005; 28:690-3.
20. Van Baal WM, Kenemans P, Van der Mooren MJ et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 1999; 81:925-8.
21. Silvestri A, Gebara O, Vitale C et al. Increased level of CRP after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation. 2003; 107:3165-9.
22. Hanna FW, Issa BG. Hyperlipidemia and cardiovascular disease: C-reactive protein and atherosclerosis - new dimensions. Curr Opin Lipidol. 2002; 13:101-3. Editorial.
23. Woodward M, Lowe GD, Francis LM et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004; 2:1934-40.
24. Jialal I, Stein D, Balis D et al. Effect of hydroxylmethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation. 2001; 103:1933-5.
25. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
26. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of an intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA. 2004; 291:1071-80.
27. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352:29-38.
28. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286:64-70.
29. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers in inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-43.
30. Abbate A, Biondi-Zoccai GG, Brugaletta S et al. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med. 2003; 3:375-84.
31. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344:1959-65.
32. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279:1615-22.
33. Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotrophy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006; 26:85S-97S.
34. Ridker PM, for the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108:2292-7.